Defunct Company
Total Trials
21
As Lead Sponsor
7
As Collaborator
14
Total Enrollment
974
NCT00405587
Safety Study of PLX4032 in Patients With Solid Tumors
Phase: Phase 1
Role: Lead Sponsor
Start: Nov 30, 2006
Completion: Feb 29, 2016
NCT01004861
Safety Study of PLX108-01 in Patients With Solid Tumors
Role: Collaborator
Start: Oct 1, 2009
Completion: Oct 25, 2018
NCT01090570
Safety, Pharmacokinetic (PK), Pharmcodynamic (PD), and Drug-Drug Interaction of PLX3397 in Patients With Rheumatoid Arthritis Who Are Receiving Methotrexate
Start: May 31, 2010
Completion: Not specified
NCT01282684
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PLX5622 in Healthy Adult Volunteers
Start: Jan 31, 2011
Completion: Apr 30, 2011
NCT01217229
Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma
Phase: Phase 2
Start: Mar 3, 2011
Completion: Apr 26, 2012
NCT01329991
Phase 1b Study of PLX5622 in Rheumatoid Arthritis Patients Who Are Receiving Methotrexate
Start: May 31, 2011
Completion: Oct 31, 2011
NCT01349049
Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Phase: Phase 1/2
Start: Nov 21, 2011
Completion: Jan 9, 2018
NCT01349036
A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma
Start: Dec 3, 2011
Completion: Nov 5, 2013
NCT01499043
Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)
Start: May 25, 2012
Completion: Mar 11, 2013
NCT01525602
Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors
Start: May 31, 2012
Completion: Feb 28, 2018
NCT01596751
Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer
Start: Jul 12, 2012
Completion: Jul 5, 2019
NCT01790503
A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma
Start: Jul 18, 2013
Completion: Mar 4, 2020
NCT01804530
Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors
Start: Aug 31, 2013
Completion: Jan 24, 2018
NCT01826448
A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma
Start: Nov 5, 2013
Completion: Sep 22, 2014
NCT02401815
CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors
Start: Mar 6, 2015
Completion: May 11, 2020
NCT02452424
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
Start: Jul 2, 2015
Completion: Oct 12, 2018
NCT02673736
A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor
Start: Feb 29, 2016
Completion: Jan 31, 2018
NCT02683395
A Study of PLX51107 in Advanced Malignancies
Start: Mar 31, 2016
Completion: Sep 30, 2018
NCT02777710
Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers
Start: Jun 30, 2016
Completion: Dec 31, 2019
NCT03158103
A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
Start: Apr 15, 2017
Completion: Apr 28, 2021
NCT04910152
Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD
Start: Apr 19, 2022
Completion: Sep 28, 2023